"We have to tell them we don't have any studies enrolling right now," said Dr. Keith Heinzerling, director of the institute's TRIP Center.
The panel also has oversight over research in the burgeoning field of psychedelics, which is developing potential treatments for depression.
[
add
]
[
|
|
...
]